Synthesis and Pharmacological Evaluation of Thiopyran Analogues of the Dopamine D3 Receptor-Selective Agonist (4aR,10bR)-(+)-trans-3,4,4a,10b- Tetrahydro-4-n-propyl-2H,5H-benzopyrano[4,3-b]-1,4-oxazin-9-ol (PD 128907)
journal contributionposted on 29.06.2000 by L. Alexander van Vliet, Nienke Rodenhuis, Durk Dijkstra, Håkan Wikström, Thomas A. Pugsley, Kevin A. Serpa, Leonard T. Meltzer, Thomas G. Heffner, Lawrence D. Wise, Mary E. Lajiness, Rita M. Huff, Kjell Svensson, Staffan Sundell, Max Lundmark
Any type of content formally published in an academic journal, usually following a peer-review process.
Benzopyranoxazine (+)-7 (PD 128907) is the most dopamine (DA) D3 receptor-selective agonist presently known. The only structural feature which distinguishes 7 from the analogous nonselective naphthoxazines is an oxygen atom in the 6-position. To extend this series of tricyclic DA agonists we used a classic bioisoster approach and synthesized thiopyran analogues of 7, which have a sulfur atom in the 6-position. We prepared trans-4-n-propyl-3,4,4a,10b-tetrahydro-2H,5H-benzothiopyrano[4,3-b]-1,4-oxazin-9-ol (9, trans-9-OH-PTBTO), its enantiomers ((+)-9 and (−)-9), the racemic cis-analogue (10), and the racemic trans-sulfoxide (11) and studied the potency and selectivity for DA receptors of these compounds. As with other rigid DA agonists, the highest affinity for DA receptors resided in one of the enantiomers, in this case the (−)-enantiomer of 9. On the basis of a single-crystal X-ray analysis of a key intermediate, the absolute configuration of (−)-9 was found to be 4aS,10bR, which is homochiral with (+)-(4aR,10bR)-7. In contrast to (+)-7 however, (−)-9 displayed no selectivity for any of the DA receptors. In addition, it has affinity for 5HT1A receptors. (±)-cis-4-n-Propyl-3,4,4a,10b-tetrahydro-2H,5H-benzothiopyrano[4,3-b]-1,4-oxazin-9-ol (10), which was expected to be inactive, displayed affinity and selectivity for the DA D3 receptor, whereas the sulfoxide 11 displayed some DA D3 selectivity, but with a lower affinity. Further pharmacological evaluation revealed that (−)-9 is a very potent full agonist at DA D2 receptors and a partial agonist at DA D3 receptors. The cis-analogue (±)-10 displayed the same profile, but with lower potency. These findings were confirmed in vivo: in reserpinized rats (−)-9 displayed short-acting activation of locomotor activity (DA D2 agonism) and also lower lip retraction and flat body posture, (5HT1A agonism). Compound (±)-10 had no effect on locomotor activity. In unilaterally 6-OH-DA lesioned rats, (−)-9 gave short-acting locomotor activation. Furthermore, in microdialysis studies in rat striatum, (−)-9 potently decreased DA release, confirming its activation of presynaptic DA D2 receptors.